Keryx Biopharmaceuticals, Inc. Announces Third Quarter and

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Keryx Biopharmaceuticals, Inc. Announces Third Quarter and Nine Month 2014 Financial Results

NEW YORK, Nov. 6, 2014 (GLOBE NEWSWIRE) -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX ), a biopharmaceutical company focused on bringing innovative therapies to market for patients suffering from renal disease (the "Company" or "Keryx"), today announced its financial results for the third quarter ended September 30, 2014. At September 30, 2014, the Company had cash, cash equivalents, interest receivable and investment securities of $118.4 million, as compared to $55.7 million at December 31, 2013.

"The third quarter of 2014 was one of tremendous achievement at Keryx," said Ron Bentsur, Chief Executive Officer of Keryx. "With the approval of Ferric Citrate we are now prepared to bring a new treatment option to patients with chronic kidney disease (CKD) on dialysis who have elevated serum phosphorus levels, and enter a $1.3 billion market in the United States. Additionally, during the quarter, we initiated a Phase 3 pivotal study to evaluate Ferric Citrate as a treatment for iron deficiency anemia (IDA) in patients with stages 3 – 5 CKD. The near-term opportunity for this drug, as well as the longer-term expansion opportunity, represent key areas of potential growth for our company."

Business Highlights

  • Ferric Citrate was approved by the U.S. Food and Drug Administration (FDA) on September 5, 2014 for the control of serum phosphorus levels in CKD patients on dialysis. Keryx plans to launch Ferric Citrate in the United States in December. In preparation for launch, the Company has completed the hiring of its field sales force and has finalized the product's promotional materials and campaign.
     
  • The Company has initiated a phase 3 clinical study of Ferric Citrate for the treatment of iron deficiency anemia in patients with stages 3 – 5 CKD, who have previously not responded to oral iron therapy. This placebo controlled study will enroll 230 patients and will evaluate changes in hemoglobin as the primary endpoint. Keryx is planning to submit the results of this study, if successful, to the FDA as a supplemental new drug application seeking label expansion of Ferric Citrate.
     
  • Several publications and presentations of Ferric Citrate data have occurred or are slated to occur. In July, the Journal of the American Society of Nephrologists published a manuscript that details the data from the long-term phase 3 clinical study of Ferric Citrate in the dialysis patient population. Additionally, next week, at the annual meeting of the American Society of Nephrologists key Ferric Citrate related abstracts will be presented.
     
  • In October 2014, following the regulatory approval of ferric citrate in Japan earlier this year, the Japan patent office granted patent term extensions for patents #4964585 and #4173553, which extended the terms of these patents in Japan to November 2025 and November 2022, respectively.

Greg Madison, Chief Operating Officer of Keryx, added, "Since receiving FDA approval of Ferric Citrate on September 5 th , we have been highly focused on finalizing all of our launch plans, including engaging with payers and hiring our sales team. With just a few weeks to go before the expected launch of Ferric Citrate, leveraging the strength of our commercial team, we have put the key components in place to ensure that we are well-positioned for launch."

Third Quarter and Nine Months Ended September 30, 2014 Financial Results

At September 30, 2014, the Company had cash, cash equivalents, interest receivable and investment securities of $118.4 million, as compared to $55.7 million at December 31, 2013. In January 2014, the Company completed an underwritten public offering of common stock, which provided proceeds to the Company of approximately $107.5 million, net of underwriting discounts and offering expenses of approximately $7.5 million. In February 2014, the Company received a $10.0 million milestone payment from its Japanese partner for Ferric Citrate, Japan Tobacco Inc. and Torii Pharmaceutical Co. ("JT & Torii"), related to the manufacturing and marketing approval of ferric citrate in Japan in January 2014.

The net loss for the third quarter ended September 30, 2014 was $35.3 million, or $0.38 per share, compared to a net loss of $15.7 million, or $0.19 per share, for the comparable quarter in 2013, representing an increase in net loss of $19.6 million. As described below, the net loss for the third quarter ended September 30, 2014 included a $3.0 million one-time FDA approval milestone payment to Ferric Citrate's licensor and $8.2 million of non-cash stock-based compensation expense, primarily related to the vesting of FDA approval milestone equity grants. For the third quarter ended September 30, 2014, research and development expenses increased by $8.4 million to $19.1 million, as compared to $10.7 million for the three months ended September 30, 2013, due, in part, to a $4.6 million increase in non-cash stock-based compensation expense primarily related to the vesting of milestone-based equity grants upon the FDA approval of Ferric Citrate. The increase in research and development expenses was also due to costs associated with the manufacturing of pre-approval inventory, and a $3.0 million one-time milestone payment to the licensor of Ferric Citrate, for our achievement of FDA approval of Ferric Citrate in September 2014. For the third quarter ended September 30, 2014, selling, general and administrative expenses increased by $11.4 million to $16.5 million, as compared to $5.1 million for the three months ended September 30, 2013, primarily related to a $6.2 million increase in pre-commercial/commercial activities and associated personnel costs in preparation for the commercialization of Ferric Citrate and a $2.8 million increase in non-cash stock-based compensation expense primarily related to increased selling, general and administrative personnel.

The net loss for the nine months ended September 30, 2014 was $71.2 million, or $0.79 per share, compared to a net loss of $29.1 million, or $0.36 per share, for the comparable period in 2013, representing an increase in net loss of $42.1 million. In January 2014, the Company recorded license revenue of $10.0 million for the milestone payment received from its Japanese partner for Ferric Citrate, JT & Torii, as discussed above. For the nine months ended September 30, 2014, research and development expenses increased by $21.4 million to $45.7 million, as compared to $24.3 million for the nine months ended September 30, 2013, primarily due to costs associated with the manufacturing of pre-approval inventory and the submission of our Marketing Authorization Application (MAA) filing, a $5.3 million increase in non-cash stock-based compensation expense primarily related to the vesting of milestone-based equity grants upon the FDA approval of Ferric Citrate, as well as $5.0 million of milestone payments to the licensor of Ferric Citrate related to the regulatory approvals of Ferric Citrate in the U.S. and Japan. Selling, general and administrative expenses increased by $23.9 million to $36.0 million for the nine months ended September 30, 2014, as compared to $12.1 million for the nine months ended September 30, 2013, primarily related to a $11.7 million increase in pre-commercial/commercial activities and associated personnel costs in preparation for the commercialization of Ferric Citrate and a $6.1 million increase in non-cash stock-based compensation expense primarily related to increased selling, general and administrative personnel.

Conference Call Information

Keryx will host an investor conference call today, Thursday, November 6, 2014, at 8:00am ET to discuss the Company's third quarter 2014 financial results and provide a business outlook for the remainder of 2014. In order to participate in the conference call, please call (888) 396-2320 (U.S.), (774) 264-7560 (outside the U.S.), call-in ID: KERYX.

A telephone replay will be available from approximately 11:00 a.m. ET on November 6, 2014 through midnight November 20, 2014. To access a replay of the conference call, dial (855) 859-2056 from the United States or (404) 537-3406 for international access. The pass code for the replay is 23434912. The audio recording of the conference call will also be available for replay at http://www.keryx.com , for a period of 15 days after the call.

About Ferric Citrate

Ferric Citrate was approved by the U.S. Food and Drug Administration on September 5, 2014 and is indicated in the U.S. for the control of serum phosphorus levels in patients with chronic kidney disease (CKD) on dialysis. Keryx plans to make Ferric Citrate available to U.S. dialysis patients in early December.

In January 2014, ferric citrate was approved for the treatment of patients with all stages of CKD in Japan, where it is being marketed as Riona® by Keryx's Japanese partner, JT & Torii. 

Keryx has filed a Marketing Authorization Application (MAA) with the European Medicines Agency (EMA), seeking the approval of Ferric Citrate as a treatment of hyperphosphatemia in patients with CKD, including dialysis and non-dialysis dependent patients, and that application is currently under review.

Ferric Citrate is also being developed in the U.S. as a treatment for iron deficiency anemia in patients with Stage 3 to 5 non-dialysis dependent CKD. The pivotal Phase 3 study in this indication commenced in September 2014.

For Full Prescribing Information for Ferric Citrate, please visit http://www.keryx.com/wp-content/uploads/Keryx...ate_PI.pdf .

Important Safety Information about Ferric Citrate

Contraindication:  Patients with an accumulation of iron in their body, e.g. hemochromatosis, should not take Ferric Citrate.

Iron Overload:  Iron absorption from Ferric Citrate may lead to increased iron in storage sites. Iron parameters should be monitored prior to and while on Ferric Citrate. Patients receiving IV iron may require a reduction in dose or discontinuation of IV iron therapy.

Accidental Overdose of Iron:  Keep Ferric Citrate away from children as it contains iron. Accidental overdose of iron containing products is a leading cause of fatal poisoning in children under 6 years of age. Call a poison control center or your physician in case of an accidental overdose in a child.

Patients with Gastrointestinal Bleeding or Inflammation:  Safety has not been established for these patients.

Adverse Events: The most common adverse events with Ferric Citrate were diarrhea (21%), nausea (11%), constipation (8%), vomiting (7%) and cough (6%). Gastrointestinal adverse reactions were the most common reason for discontinuing Ferric Citrate (14%).

Ferric Citrate contains iron and may cause dark stools, which is considered normal with oral medications containing iron.

Drug Interactions:  Doxycycline should be taken at least 1 hour before Ferric Citrate.  


Keryx Biopharmaceuticals, Inc.
Selected Consolidated Financial Data
(In Thousands, Except Share and Per Share Amounts)
 
Statements of Operations Information (Unaudited):
  Three Months Ended
 September 30,
Nine Months Ended 
September 30,
         
  2014 2013 2014 2013
  REVENUE:        
  License revenue $ 256 $ -- $ 10,256 $ 7,000
           
  OPERATING EXPENSES:        
  License Expenses 154 -- 154 --
  Research and development 19,053 10,670 45,687 24,277
  General and administrative 16,447 5,062 36,007 12,067
  TOTAL OPERATING EXPENSES 35,654 15,732 81,848 36,344
           
  OPERATING LOSS (35,398) (15,732) (71,592) (29,344)
           
  OTHER INCOME:        
  Interest and other income, net 109 81 359 280
           
  NET LOSS $ (35,289) $ (15,651) $ (71,233) $ (29,064)
           
  NET LOSS PER COMMON SHARE        
  Basic and diluted net loss per common share $ (0.38) $ (0.19) $ (0.79) $ (0.36)
           
  SHARES USED IN COMPUTING NET LOSS PER COMMON SHARE        
  Basic and diluted 91,846,588 81,823,415 90,639,072 80,531,785
 
Balance Sheet Information:
  September 30, 2014 December 31, 2013*
  (unaudited)  
Cash, cash equivalents, interest receivable and investment securities $ 118,384 $ 55,696
Total assets $ 126,908 $ 60,766
Accumulated deficit $ (510,573) $ (439,340)
Stockholders' equity  $ 98,708 $ 45,400
 
* Condensed from audited financial statements.

About Keryx Biopharmaceuticals, Inc.

Keryx Biopharmaceuticals, headquartered in New York, is focused on bringing innovative therapies to market for patients with renal disease. The Company's lead product, Ferric Citrate, is approved in the United States for the control of serum phosphorus levels in patients with chronic kidney disease on dialysis. Keryx plans to commercially launch Ferric Citrate in the U.S. in the fourth quarter of 2014. For more information about Keryx, please visit www.keryx.com .

Cautionary Statement

Some of the statements included in this press release, particularly those relating to the launch of Ferric Citrate, the results of clinical trials, the potential clinical benefits to be derived from Ferric Citrate, regulatory submissions and approvals, and any business prospects for Ferric Citrate, may be forward-looking statements that involve a number of risks and uncertainties. For those statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Among the factors that could cause our actual results to differ materially are the following: whether Ferric Citrate will be successfully launched and marketed in the US; the risk that the EMA ultimately deny approval of the MAA; whether Riona® will be successfully launched and marketed by our Japanese partner, JT & Torii; and other risk factors identified from time to time in our reports filed with the Securities and Exchange Commission. Any forward-looking statements set forth in this press release speak only as of the date of this press release. We do not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. This press release and prior releases are available at http://www.keryx.com . The information found on our website is not incorporated by reference into this press release and is included for reference purposes only.

Amy Sullivan Vice President, Corporate Development and Public Affairs Tel: 617.466.3447 e-mail:

Scroll down for more posts ▼

Top 10 Most Recent News Articles

ETCO Targets the Unflashy Weak Link in Battery Storage

Updated Category News Views 16

A battery cabinet can look impressive right up until one lousy connection becomes the problem nobody budgeted for. ETCO Incorporated’s new lineup of standard and custom connectors and terminals goes after that unglamorous part of battery energy storage systems: the physical handoff points carrying power, grounding equipment, and tying auxiliary components together. It...

Continue Reading
Frontline Claims Survey Tests AI's Real Desk Impact

Updated Category News Views 92

Claims software can look brilliant in a conference-room demo and still create a fresh pile of headaches for the person handling a real injured worker’s file. That is why the 2026 Workers’ Compensation Benchmarking Study opening its survey to frontline claims professionals matters more than the usual industry questionnaire. This is an operating-reality check, not just...

Continue Reading
My Home Delivery's Bold Move in Big & Bulky Sector

Updated Category News Views 304

Redefining Big & Bulky Deliveries with AI Let me tell you, the logistics world isn't for the timid, and My Home Delivery (MHD) is swinging for the fences with their latest tech platform. These folks are rolling out an AI-driven system that promises to turn the bulky goods market on its head. Imagine moving your brand new fridge or that king-size bed across town without...

Continue Reading
U.S. Patriot's Veteran Hiring Earns a Real National Nod

Updated Category News Views 38

A workforce award can be cheap wallpaper, but this one has some heft. U.S. Patriot, the veteran-founded and veteran-led military goods retailer owned by GALLS, landed on Military Times’ 2026 Best for Vets: Employers list, placing third in retail and first in Kentucky. The recognition covers 250 organizations, and this is U.S. Patriot’s fourth consecutive appearance....

Continue Reading
Redseer's $5M Bet on Faster MENA Decision Intelligence

Updated Category News Views 65

Speed has become the expensive commodity in Middle Eastern commerce, and Redseer is putting roughly $5 million behind the idea that executives will pay to get it. Its newly launched Benchmarks MENA 2.0 platform combines proprietary market data with strategic advisory across nine MENA markets. That sounds like another corporate dashboard pitch until you consider the target...

Continue Reading
Hexaware’s Seven-Year Client Signal Is Worth Watching

Updated Category News Views 164

Seven straight years of recognition is harder to shrug off than one shiny plaque on a corporate shelf. Hexaware Technologies announced on November 18, 2026 that it received the ISG Star of Excellence Award in the Client Champion category, marking its seventh consecutive year of recognition in that awards program. For investors following IT services, that is a...

Continue Reading
Workday GO for Financials Targets the Messy Middle

Updated Category News Views 146

Spreadsheets rarely die gracefully; they get buried under approvals, reconciliations, and the frantic scavenger hunt before an audit. Workday is aiming straight at that unpleasant moment with Workday GO for Financials, announced November 18 at Workday Rising EMEA in Barcelona. The pitch is not terribly romantic, thank goodness. It is a simpler way for growing companies to...

Continue Reading
Exiger's CEO Honored for Military Support Excellence

Updated Category News Views 135

Recognizing Civilian and Military Leadership When you hear "recognition in the military sector," it isn't just a pat on the back. It's a whole parade of brass hats and high-flyers giving their nods. So, November 10th wasn't just any regular day—Brandon Daniels, CEO of Exiger, gets a shiny, prestigious Five-Star Award for his "extraordinary support" of our military...

Continue Reading
A Parish Memoir That Sends Its Proceeds Back Home

Updated Category News Views 23

Some books arrive with a thunderclap; this one shows up carrying a folding chair, a prayer book, and a memory that refuses to leave. You Give Them Something to Eat, the new memoir from Fr. Michael J Rieder, is built from more than a hundred short chapters rather than one grand, polished life story. That choice fits the material. Parish life is rarely a clean parade of...

Continue Reading
Discount Tire’s $10 Correction Matters This Black Friday

Updated Category News Views 0

A ten-dollar correction is not a catastrophe, but it is precisely the sort of loose screw that deserves a glance before Black Friday shouting gets underway. Discount Tire says an earlier version of its Nov. 17, 2026 promotion release listed combined instant savings of $390 when the correct maximum is $380. The company issued the correction and supplied a revised release....

Continue Reading

Top 5 Most Recently Viewed Articles

SK Chemicals Delivers Sustainable Innovation at ECS 2025

Updated Category News Views 484

SK Chemicals at the European Coatings Show 2025 SK chemicals has proudly participated in the European Coatings Show (ECS) 2025, marking a significant moment for the company as it engages in marketing its innovative materials. This event is known for attracting key players in the coatings and paint sector, and this year was no exception, with over 1,000 exhibitors and more...

Continue Reading
Analyzing TJX Companies' Increased Short Interest Trends

Updated Category News Views 230

Understanding the Rise in TJX Companies' Short Interest The short interest for TJX Companies (NYSE: TJX) has seen a significant uptick, now standing at 14.55 million shares sold short, which constitutes 1.29% of its float. This marks a 21.7% increase since the prior reporting period. Given the current trading volume, traders would require approximately 2.49 days to cover...

Continue Reading
IGT Expands Collaboration with La Française des Jeux for Instant Tickets

Updated Category News Views 69

IGT Expands Collaboration with La Française des Jeux Company to deliver top-performing instant ticket games to one of the world's largest lotteries International Game Technology PLC (NYSE: IGT) has officially entered a three-year partnership with La Française des Jeux (FDJ), the esteemed operator of the French National Lottery. This significant agreement follows a...

Continue Reading
Archer Expands Footprint with New Manufacturing Facility Opening

Updated Category News Views 267

Archer Expands Footprint with New Manufacturing Facility Opening New state-of-the-art facility doubles manufacturing capacity and adds more than 200 local jobs Archer, one of the fastest-growing meat snack brands in the U.S., is celebrating a significant milestone with the grand opening of its new manufacturing facility. This latest addition in Vernon, California,...

Continue Reading
Bumble Faces Downgrade from KeyBanc Amid Revenue Concerns

Updated Category News Views 309

Bumble Inc (NASDAQ: BMBL) took a hit when KeyBanc downgraded its rating from 'Overweight' to 'Sector Weight', shaking the confidence of many investors. The downgrade was more than just a simple reassessment; it became a catalyst for a stock value decline in premarket trading that had traders watching their screens with bated breath. KeyBanc Downgrade: A Harbinger of...

Continue Reading